Emcure Launches Poviztra: Revolutionizing Weight Management in India

Published: December 22, 2025 | Pharmaceutical News India

In a major milestone for Indian healthcare, Emcure Pharmaceuticals has announced the commercial launch of Poviztra® (Semaglutide). As the first Indian company to exclusively commercialize this blockbuster molecule from Novo Nordisk, Emcure is set to transform the landscape of obesity treatment in the country.

The Breakthrough: Poviztra is a once-weekly semaglutide injection specifically indicated for chronic weight management. It offers the same efficacy as global brands but is tailored for the Indian market through Emcure’s extensive reach.

Affordable Access to Global Innovation

One of the most significant aspects of this launch is the pricing strategy. Emcure has positioned Poviztra as a highly competitive option:

• Starting Price: ₹8,790 per month (includes 4 weekly doses).
• Market Comparison: This price point significantly undercuts recent competitors, making advanced GLP-1 therapy accessible to a broader patient base in Tier-2 and Tier-3 cities.

Dosing and Strengths

Poviztra is administered via a user-friendly pen device once a week. The treatment follows a gradual dose-escalation schedule to ensure patient comfort:

Strength	Usage Phase
0.25 mg	Initiation Phase (Month 1)
0.5 mg - 1.7 mg	Escalation Phase
2.4 mg	Maintenance Dose

Clinical Indications

The drug is indicated for adults with a Body Mass Index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) when accompanied by at least one weight-related health condition such as hypertension or Type 2 diabetes. Additionally, it is proven to reduce the risk of major adverse cardiovascular events (MACE) in eligible patients.

Prioritize Your Health

Poviztra is a prescription-only medication. Consult a certified medical professional or endocrinologist to discuss if this therapy is suitable for your weight-management journey.